# A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

> **NCT04958031** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 41 (actual)

## Conditions studied

- Apathy in Dementia

## Interventions

- **DRUG:** CVL-871 1.0 mg
- **DRUG:** CVL-871 3.0 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04958031
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-22
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Sponsor Decision - Not Safety Related
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04958031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04958031, "A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04958031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*